Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569_0003 [NCT05162586]).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
532 participants in 4 patient groups
Loading...
Central trial contact
Communication Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal